Literature DB >> 27375123

Refining the Role of Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia as Novel Therapies Emerge.

Riad El Fakih1, Mohamed A Kharfan-Dabaja2, Mahmoud Aljurf3.   

Abstract

Acute lymphoblastic leukemia (ALL) is a rare adult neoplasm. The disorder consists of precursor B or T phenotypes. In the pediatric population, ALL was a success story in that 80% of children with ALL enjoy long-term survival. In adults, similar complete remission rates are achieved with current induction regimens; however, less than 50% of patients are alive at 5 years, with most deaths due to relapsed disease. Accordingly, optimizing post remission consolidation therapy might improve in outcomes. Such strategies may include chemotherapy and autologous or allogeneic transplant. Moreover, the ability to modify such therapy based on better disease risk stratification while taking into account patient characteristics such as performance status and presence of comorbidities is necessary to tailor treatment accordingly. Here, we review available medical literature on the use of hematopoietic cell transplantation as a consolidation modality in the treatment of adult ALL.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALL; Hematopoietic cell transplantation

Mesh:

Year:  2016        PMID: 27375123     DOI: 10.1016/j.bbmt.2016.06.027

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

Review 1.  Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?

Authors:  Rishi Dhawan; David I Marks
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

2.  CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission.

Authors:  Mohamed A Kharfan-Dabaja; Myriam Labopin; Ali Bazarbachi; Urpu Salmenniemi; Stephan Mielke; Patrice Chevallier; Marie Thérèse Rubio; Marie Balsat; Pietro Pioltelli; Anne-Lise Menard; Gerard Socié; Anne Huynh; Nicolaas Schaap; Arancha Bermúdez Rodríguez; Jan J Cornelissen; Ibrahim Yakoub-Agha; Mahmoud Aljurf; Sebastian Giebel; Eolia Brissot; Zina Peric; Arnon Nagler; Mohamad Mohty
Journal:  Hemasphere       Date:  2022-10-12

3.  Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients.

Authors:  Li Ding; Dong-Mei Han; Hong-Min Yan; Jie-Xin Zhou; Xiao-Li Zheng; Ling Zhu; Mei Xue; Jing Liu; Ning Mao; Zi-Kuan Guo; Hong-Mei Ning; Heng-Xiang Wang; Heng Zhu
Journal:  Bone Marrow Transplant       Date:  2022-04-25       Impact factor: 5.174

4.  Approach to the Adult Acute Lymphoblastic Leukemia Patient.

Authors:  Valentina Sas; Vlad Moisoiu; Patric Teodorescu; Sebastian Tranca; Laura Pop; Sabina Iluta; Sergiu Pasca; Cristina Blag; Sorin Man; Andrei Roman; Catalin Constantinescu; Ioana Rus; Mihail Buse; Bogdan Fetica; Mirela Marian; Cristina Selicean; Ioana Berindan-Neagoe; Bobe Petrushev; Horia Bumbea; Alina Tanase; Mihnea Zdrenghea; Shigeo Fuji; Shigehisa Kitano; Ciprian Tomuleasa
Journal:  J Clin Med       Date:  2019-08-06       Impact factor: 4.241

Review 5.  Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.

Authors:  Omar Castaneda Puglianini; Nikolaos Papadantonakis
Journal:  Ther Adv Hematol       Date:  2020-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.